Beranda › Leukemia Limfositik Kronis › Maine
Uji klinis Leukemia Limfositik Kronis di Maine
6 studi untuk Leukemia Limfositik Kronis mencari peserta di lokasi di Maine.
Kota di Maine
Teks studi resmi (Bahasa Inggris)
Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
- MaineHealth Maine Medical Center - Portland, Portland
- MaineHealth Cancer Care and IV Therapy - South Portland, South Portland
Menerima pesertaFase 3
Usia 65 ke atas · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT07321652Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Harold Alfond Center for Cancer Care, Augusta
- MaineHealth Waldo Hospital, Belfast
- Lafayette Family Cancer Center-EMMC, Brewer
- dan 9 lainnya
Menerima pesertaStudi observasionalSukarelawan sehat diterima
Usia 40 hingga 75 · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT05334069A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Secondary Antibody Deficiency Associated With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma
- Study Site 105, Westbrook
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 1 Okt 2026 · NCT07582432Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
- Harold Alfond Center for Cancer Care, Augusta
- MaineHealth Cancer Care and IV Therapy - Brunswick, Brunswick
- Mid Coast Hospital, Brunswick
- dan 4 lainnya
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 30 Sep 2026 · NCT04269902Fixed Duration Pirtobrutinib and Obinutuzumab in Chronic Lymphocytic Leukemia
- New England Cancer Specialists, Scarborough
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 21 Jan 2026 · NCT06333262Zanubrutinib and Venetoclax in CLL (ZANU-VEN)
- New England Cancer Specialists, Scarborough
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 5 Des 2025 · NCT05168930Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.